Chinese Neurological Association, CMNN & ECF joint Symposium

The European Charcot Foundation, the Chinese Neurological Association and the Chinese Medical Network of Neuroinflammation are jointly organising a digital conference on "Multiple Sclerosis and related disorders" on Saturday September 19th and Sunday September 20th, 2020.

ECF, Chinese Neurological Association & CMNN joint Symposium "Multiple Sclerosis and related disorders"

Saturday 19 September 2020, 14:00 - 17:32, China Standard Time (UTC +8)

Chairs: prof Fu-Dong Shi & prof Giancarlo Comi

  • 14:00 - 14:20 (UTC +8):
    How to optimize treatment in relapsing remitting MS

    Prof Dr Gilles Edan (Rennes, France)
  • 14:20 - 14:40 (UTC +8):
    MS treatment: looking to the future

    Prof Dr Hans-Peter Hartung (Dusseldorf, Gemany)
  • 14:40 - 15:00 (UTC +8):
    Association of ABCG2 mutation with terifluramine exposure in relapsing MS patients for 24 weeks: research principle and design
    Wei Qiu
  • 15:00 - 15:08 (UTC +8):
    Risk of COVID-19 infection in MS and neuromyelitis optic spectrum disease
    Moli Fan
  • 15:08 - 15:16 (UTC +8):
    Regulation of Kv1.3 pathway blocker on blood brain barrier in MS
    Yipeng Zhao
  • 15:16 - 15:24 (UTC +8):
    Immunomodulatory mechanism of intraluminal rapamycin on Gas6 / TAM pathway in EAE mice
    Xiaolin Li
  • 15:24 - 15:32 (UTC +8):
    Therapeutic effect of DC induced by silencing MyD88 on EAE
    Lingling Liu
  • 15:32 - 16:00 (UTC +8):
    Satellite Symposium
  • 16:00 - 16:20 (UTC +8):
    From clinical trials to clinical practices in progressive MS

    Prof Dr Giancarlo Comi (Milan, Italy)
  • 16:20 - 16:40 (UTC +8):
    A novel NMOSD mouse model based on reversible blood brain barrier opening technology
    Yangtai Guan
  • 16:40 - 17:00 (UTC +8):
    Long term efficacy of mycophenolate mofetil in treatment of myelin oligodendrocyte glycoprotein antibody-associated diseases: a prospective study
    Yan Xu
  • 17:00 - 17:08 (UTC +8):
    MRI features of intracranial lesions in patients with MOG antibody disease
    Haiqing Li
  • 17:08 - 17:16 (UTC +8):
    Clinical characteristics and prognosis of MOG antibody associated encephalitis
    Hexiang Yin
  • 17:16 - 17:24 (UTC +8):
    A NMOSD mouse model based on low frequency ultrasound combined with microbubble Technology
    Jiaying Luo
  • 17:24 - 17:32 (UTC +8):
    Clinical characteristics of NF155 IgG positive patients in neuromyelitis optical spectrum diseases
    Linjie Zhang

Sunday 20 September 2020, 08:30 - 10:00 am (CST)

  • 08:30 - 08:50 (UTC +8):
    NMOSD: pathophysiological and clinical aspects

    Prof Dr Kazuo Fujihara (Fukushima, Japan)
  • 08:50 - 09:10 (UTC +8):
    NMOSD treatment and monitoring

    Prof Dr Fu-Dong Shi (Beijing, China)
  • 09:10 - 09:30 (UTC +8):
    Diagnosis and treatment strategy of "special population" in patients with NMOSD.
    Jiawei Wang
  • 09:30 - 09:38 (UTC +8):
    Efficacy and safety of reduced rituximab
    in the treatment of NMOSD under B cell monitoring: a pilot study.
    Qun Xue
  • 09:38 - 09:46 (UTC +8):
    Immunotherapy for female NMOSD patients of childbearing age.
    Tingting Yang
  • 09:46 - 09:54 (UTC +8)
    Intravenous immunogloblin in acute episode of NMOSD, an real world observation.
    Xindi Li
  • 09:54 - 10:00 (UTC +8):
    Association between basal ganglia, nucleus accumbens and fatigue in patients with NMOSD.
    Hongxi Chen

Programme flyer

http://tmcdlab.com/ - http://bjtjcni.com - http://www.newterrain.cn/

Zhuhai, China
September 19, 2020 - September 20, 2020